基于中医药理论的ERCP术后POCD预防策略:TEAS的应用与管理

注册号:

Registration number:

ITMCTR2025000996

最近更新日期:

Date of Last Refreshed on:

2025-05-15

注册时间:

Date of Registration:

2025-05-15

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于中医药理论的ERCP术后POCD预防策略:TEAS的应用与管理

Public title:

Prevention Strategy for Post-ERCP Cognitive Dysfunction (POCD) Based on Traditional Chinese Medicine Theory: Application and Management of Transcutaneous Electrical Acupoint Stimulation (TEAS)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于中医药理论的ERCP术后POCD预防策略:TEAS的应用与管理

Scientific title:

Prevention Strategy for Post-ERCP Cognitive Dysfunction (POCD) Based on Traditional Chinese Medicine Theory: Application and Management of Transcutaneous Electrical Acupoint Stimulation (TEAS)

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

赵利芳

研究负责人:

赵利芳

Applicant:

Zhaolifang

Study leader:

Zhaolifang

申请注册联系人电话:

Applicant telephone:

17637306376

研究负责人电话:

Study leader's telephone:

17637306376

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhaolifanggong@sina.cn

研究负责人电子邮件:

Study leader's E-mail:

zhaolifanggong@sina.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

河南省新乡市金穗大道56号

研究负责人通讯地址:

河南省新乡市金穗大道56号

Applicant address:

No. 56 Jinsui Avenue Xinxiang City Henan Province China

Study leader's address:

No. 56 Jinsui Avenue Xinxiang City Henan Province China

申请注册联系人邮政编码:

Applicant postcode:

453000

研究负责人邮政编码:

Study leader's postcode:

453000

申请人所在单位:

新乡市中心医院

Applicant's institution:

Xinxiang Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025-039-01(K)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

新乡市中心医院伦理审查委员会

Name of the ethic committee:

Ethics Review Committee of Xinxiang Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025/1/22 0:00:00

伦理委员会联系人:

姜红会

Contact Name of the ethic committee:

Jiang Honghui

伦理委员会联系地址:

河南省新乡市金穗大道56号

Contact Address of the ethic committee:

No. 56 Jinsui Avenue Xinxiang City Henan Province China

伦理委员会联系人电话:

Contact phone of the ethic committee:

16637353251

伦理委员会联系人邮箱:

Contact email of the ethic committee:

kejiaoke123456@163.com

研究实施负责(组长)单位:

新乡市中心医院

Primary sponsor:

Xinxiang Central Hospital

研究实施负责(组长)单位地址:

河南省新乡市金穗大道56号

Primary sponsor's address:

No. 56 Jinsui Avenue Xinxiang City Henan Province China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南省

市(区县):

新乡市

Country:

China

Province:

Henan Province

City:

Xinxiang City

单位(医院):

新乡市中心医院

具体地址:

河南省新乡市金穗大道56号

Institution
hospital:

Xinxiang Central Hospital

Address:

No. 56 Jinsui Avenue Xinxiang City Henan Province China

经费或物资来源:

自筹

Source(s) of funding:

Self-financed

研究疾病:

ERCP术后认知功能障碍

研究疾病代码:

Target disease:

Postoperative Cognitive Dysfunction (POCD) following Endoscopic Retrograde Cholangiopancreatography (ERCP)

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

治疗新技术临床试验

New Treatment Measure Clinical Study

研究目的:

探索基于中医药理论的经皮穴位电刺激(TEAS)预防经内镜逆行胰胆管造影术(ERCP)术后认知功能障碍(POCD)的策略

Objectives of Study:

Exploring Strategies for Transcutaneous Electrical Acupoint Stimulation (TEAS) Based on Traditional Chinese Medicine Theory in Preventing Postoperative Cognitive Dysfunction (POCD) Following Endoscopic Retrograde Cholangiopancreatography (ERCP)

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)年龄18岁—65岁,BMI18.5-27.9kg/m2,符合行ERCP手术者;(2)美国麻醉医师协会身体状况I级至III级;(3)均无药物过敏史及禁忌症;

Inclusion criteria

(1) Aged 18–65 years with a BMI of 18.5–27.9 kg/m² and eligible for ERCP (endoscopic retrograde cholangiopancreatography); (2) American Society of Anesthesiologists (ASA) Physical Status Class I to III; (3) No history of drug allergies or contraindications to related medications.

排除标准:

(1)术前认知功能受损或简易精神状态检查量表(MMSE,<24)或蒙特利尔认知评估(MoCA,<26)评分异常;(2)心、肺、肝或肾功能明显异常;(3)创伤性脑损伤、神经系统疾病和酗酒史;(4)无法与医生有效沟通并与他们合作完成认知功能测试。

Exclusion criteria:

(1) Preoperative cognitive impairment or abnormal scores on the Mini-Mental State Examination (MMSE <24) or Montreal Cognitive Assessment (MoCA <26); (2) Significant impairment of cardiac pulmonary hepatic or renal function; (3) History of traumatic brain injury neurological disorders or alcohol abuse; (4) Inability to communicate effectively with healthcare providers or cooperate in completing cognitive function assessments.

研究实施时间:

Study execute time:

From 2025-06-01

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2025-07-01

To      2026-05-31

干预措施:

Interventions:

组别:

对照组

样本量:

40

Group:

-Control Group

Sample size:

干预措施:

假TEAS治疗(电极片贴于非穴位处且无实际电刺激输出)

干预措施代码:

Intervention:

sham TEAS treatment(non-acupoint electrode placement with no electrical stimulation delivered)

Intervention code:

组别:

干预组

样本量:

40

Group:

Intervention group

Sample size:

干预措施:

TEAS治疗

干预措施代码:

Intervention:

TEAS Treatment

Intervention code:

样本总量 Total sample size : 80

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河南省

市(区县):

新乡市

Country:

China

Province:

Henan Province

City:

Xinxiang City

单位(医院):

新乡市中心医院

单位级别:

三级甲等

Institution/hospital:

Xinxiang Central Hospital

Level of the institution:

No. 56 Jinsui Avenue Xinxiang City Henan Province China

测量指标:

Outcomes:

指标中文名:

脑源性神经营养因子(BDNF)

指标类型:

次要指标

Outcome:

BDNF

Type:

Secondary indicator

测量时间点:

术前1天、术后第1天、第3天、第7天

测量方法:

抽血化验

Measure time point of outcome:

on preoperative postoperative days 1 3 and 7

Measure method:

blood sample collection and laboratory testing

指标中文名:

术后7天内POCD 发生率

指标类型:

主要指标

Outcome:

Incidence of postoperative cognitive dysfunction (POCD)

Type:

Primary indicator

测量时间点:

术前1天、术后第1、3、7天

测量方法:

蒙特利尔认知评估量表(MoCA)、简易精神状态检查表(MMSE)认知功鞥

Measure time point of outcome:

on preoperative postoperative days 1, 3, and 7

Measure method:

MMSE、MoCA

指标中文名:

神经丝轻链蛋白(NFL)

指标类型:

次要指标

Outcome:

neurofilament light chain protein (NfL)

Type:

Secondary indicator

测量时间点:

术前1天、术后第1、3、7天

测量方法:

抽血化验

Measure time point of outcome:

on preoperative postoperative days 1 3 and 7

Measure method:

blood sample collection and laboratory testing

指标中文名:

S100β 蛋白

指标类型:

次要指标

Outcome:

S100β protein

Type:

Secondary indicator

测量时间点:

术前1天、术后第1、3、7天

测量方法:

抽血化验

Measure time point of outcome:

on preoperative postoperative days 1 3 and 7

Measure method:

blood sample collection and laboratory testing

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

运用SPSS、R等统计软件,对临床研究、动物实验、细胞实验数据进行整理、统计分析,对比组间差异,

Randomization Procedure (please state who generates the random number sequence and by what method):

Using statistical software (SPSS R etc.) to organize and analyze data from clinical studies animal experiments and cell-based experiments with comparative analysis of intergroup differences.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Pummed等网上公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

publicly available online

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF 表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF table

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统